Q2 2025 Neuland Laboratories Ltd Earnings Call Transcript
Key Points
- Neuland Laboratories Ltd (BOM:524558) reported a strong EBITA margin of 20.8% for Q2 FY25, indicating efficient cost management.
- The company has generated a free cash flow of INR 45.84 crores in H1 FY25, showcasing effective cash management.
- Neuland Laboratories Ltd is seeing increasing interest from biotech companies, which could lead to more early-stage projects and potential growth.
- The company has completed additional manufacturing facilities, which positions it for high growth in FY26 and beyond.
- Neuland Laboratories Ltd is strategically positioned to seize future opportunities by focusing on high-value molecules and enhancing customer experience.
- Total income for Q2 FY25 was INR 315.2 crores, a decrease from INR 422.84 crores in the same period last year, indicating a decline in revenue.
- The company's gross margin for the quarter decreased to 56.3% from 59.8% in the previous year, reflecting increased manufacturing costs.
- Profit after tax was significantly lower at INR 32 crores compared to INR 89.1 crores in Q2 FY24, highlighting reduced profitability.
- Neuland Laboratories Ltd expects FY25 to be flat compared to FY24, indicating limited growth prospects for the current fiscal year.
- The business is inherently variable, making it challenging to provide consistent guidance and potentially leading to investor uncertainty.
You will be disconnected because the chairperson has not arrived to start this conference and please wait while you are joined to the conference. The conference has not been initiated.
Ladies and gentlemen, good day and welcome to Newland Laboratories Limited Q2 and H1 FY25 earnings conference call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call? Please signal an operator by pressing star then zero on your Touchstone phone. Please note that this conference is being recorded.
I now hand the conference over to Mr. Ravi Udeshi from Ernst and Young.
Thank you and over to you sir.
To the Q2 and H1 FY 25 HNI conference call of Newland laboratories limited to take us through the results and to answer your questions we have with us the top management from Newland laboratories represented by Mr. Sucheth Davuluri-Vice Chairman and CEO, Mr.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
